ReviewCNS neuroscience & therapeutics2026
From Regeneration Failure to Functional Restoration: Unlocking the Neuronal-Intrinsic Regenerative Capacity as a Therapeutic Frontier for Optic Neuropathy and Glaucoma.
Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-omics Mendelian randomization analysis identifies SPATA20 as a cross-omic target in primary open angle glaucoma.International journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOptic neuropathy encompasses ocular conditions arising from traumatic or nontraumatic damage to optic nerves, causing permanent visual impairment due to retinal ganglion cell (RGC) loss and disrupted axonal connections. Glaucomatous optic neuropathy represents the most prevalent form, affecting over 70 million individuals worldwide and causing blindness in nearly 4 million people. CURRENT LIMITATIONS: Current treatments targeting elevated intraocular pressure can slow disease progression but cannot restore vision once RGC axons are lost, largely due to regeneration failure in surviving RGCs. This regenerative failure stems not merely from the presence of growth-inhibitory extrinsic factors, but crucially from diminished neuronal-intrinsic regenerative capacity in mature RGCs. MECHANISTIC INSIGHTS AND THERAPEUTIC IMPLICATIONS: This review explores how intrinsic growth barriers and inadequate activation of pro-regenerative genes impede axonal regrowth following injury, and how manipulations of these pathways facilitate axon regeneration and visual recovery in experimental models. Emerging findings suggest that these pro-regenerative molecules capable of modifying the neuronal-intrinsic regenerative capacity of RGCs can also preserve visual function in pre-clinical glaucoma models. Finally, we discuss challenges and future directions for translating these findings into therapies, including gene delivery strategies, remyelination therapeutics, and systems biology-based in silico drug screening approaches aiming to reshape the therapeutic landscape towards regenerative interventions for glaucomatous and other optic neuropathies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.